EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Thalidomide as an Adjunctive Therapy for HIV-Tuberculosis–Associated Immune Reconstitution Inflammatory Syndrome: A Case Series

S Lee-Jones iD, K Rebe iD, S Marais iD, G Meintjes iD, A Parker iD, H van der Plas iD

Open Forum Infectious Diseases · 30.10.2025 · 12 (11)

DOI: 10.1093/ofid/ofaf617 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 01.10.2025. Verfasst von S Lee-Jones und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Stellenbosch University, Cape Town, South Africa. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A small proportion of people living with human immunodeficiency virus (HIV) who have tuberculosis-related immune reconstitution inflammatory syndrome (tuberculosis-IRIS) have prolonged and complicated courses and experience poor response to corticosteroid therapy, relapse after withdrawing, or intolerability demonstrating a need for alternative immunomodulatory options. Thalidomide has been shown to have immunomodulatory effects, primarily in neurological tuberculosis in children, but there is little description of its use in adult patients.

Methods

We describe the clinical course in 7 adult patients with complicated HIV-associated tuberculosis-IRIS treated with thalidomide.

Results

The clinical manifestations included central nervous system tuberculosis (n = 4) , tuberculous adenitis (n = 2), and recurrent tuberculous psoas collection (n = 1). All patients were given thalidomide (100 mg) for 6–12 months, with favorable clinical outcomes and no adverse effects.

Conclusions

Thalidomide dosed at 100 mg/d remains an agent with clinical utility in this small subset of patients, and further research to determine optimal dosing and duration could be beneficial.

Schlagwörter

Stichwörter der Autor:innen

immune reconstitution inflammatory syndrometuberculous adenitistuberculous meningitistumor necrosis factor

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, Stellenbosch University, Cape Town, South Africa.
  • Life Vincent Pallotti Hospital, Cape Town, South Africa.
  • Division of Neurology, Department of Medicine, University of Cape Town & Neurology Research Group, Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
  • Department of Medicine and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.

ORCID-Profile: S Lee-Jones, K Rebe, S Marais, G Meintjes, A Parker, H van der Plas

Förderung

  • Wellcome Trust

Zitieren

APA

Lee-Jones, S., Rebe, K., Marais, S., Meintjes, G., Parker, A., & van der Plas, H. (2025). Thalidomide as an Adjunctive Therapy for HIV-Tuberculosis–Associated Immune Reconstitution Inflammatory Syndrome: A Case Series. Open Forum Infectious Diseases, 12(11). https://doi.org/10.1093/ofid/ofaf617

Vancouver

Lee-Jones S, Rebe K, Marais S, Meintjes G, Parker A, van der Plas H. Thalidomide as an Adjunctive Therapy for HIV-Tuberculosis–Associated Immune Reconstitution Inflammatory Syndrome: A Case Series. Open Forum Infectious Diseases. 2025;12(11). doi:10.1093/ofid/ofaf617

BibTeX
@article{LeeJones2025,
  author = {Lee-Jones, S and Rebe, K and Marais, S and Meintjes, G and Parker, A and van der Plas, H},
  title = {Thalidomide as an Adjunctive Therapy for HIV-Tuberculosis–Associated Immune Reconstitution Inflammatory Syndrome: A Case Series},
  journal = {Open Forum Infectious Diseases},
  year = {2025},
  volume = {12},
  number = {11},
  doi = {10.1093/ofid/ofaf617}
}
Kostenlos starten →